期刊文献+

帕利哌酮和利培酮对精神分裂症患者脑源性神经营养因子与事件相关电位N400的影响 被引量:12

Effects of paliperidone and risperidone treatment on brain-derived neurotrophic factor and event-related potential N400 in schizophrenia patients
原文传递
导出
摘要 目的比较帕利哌酮和利培酮对首发精神分裂症患者脑源性神经营养因子(BDNF)与事件相关脑电位N400的影响。方法首发精神分裂症患者90例,随机分为帕利哌酮组和利培酮组各45例,给予帕利哌酮(6~12 mg·d^(-1))和利培酮(3~6 mg·d^(-1))治疗12周,比较两组患者治疗前、后血清BDNF水平、事件相关脑电位N400潜伏期及波幅,并分析其与阳性与阴性症状量表(PANSS)分之间的关系。结果两组各有3例因不能耐受不良反应而脱落。两组患者治疗后血清BDNF水平均有回升,差异有显著意义(P<0.01),但组间比较无显著差异(P>0.05)。治疗后,两组患者匹配条件下的N400潜伏期缩短、波幅回升(P<0.01);非匹配条件下帕利哌酮组N400潜伏期缩短(P<0.05),而利培酮组N400波幅增高(P<0.01)。两组患者治疗后PANSS总分均明显下降(P<0.01),但组间比较无显著差异(P>0.05)。相关分析显示,帕利哌酮组PANSS减分率与血清BDNF升高值存在正相关(r=0.417,P<0.05),利培酮组未发现两者间存在相关(r=0.103,P=0.516)。结论帕利哌酮及利培酮均可提升精神分裂症患者血清BDNF水平,改善患者认知功能(N400潜伏期与波幅)。 AIM To compare the effects of paliperidone and risperidone on brain-derived neurotrophic factor(BDNF) and event-related brain potential N400 in patients with first-episode schizophrenia.METHODS Totally 90 patients with first-episode schizophrenia were randomly divid ed into the paliperidone group and the risperidone group,treated with paliperidone(6-12 mg·d^-1) and risperidone(3-6 mg·d^-1) respectively for 12 weeks.Serum BDNF concentrations and event-related potential N400 latency and amplitude were compared between the two groups before and after the treatment,and the relationship between them and scores of Positive and Negative Symptoms Scale(PANSS) were calculated.RESULTS There were 3 patients in each group dropped out,due to the irresistance of the adverse drug reactions.After the treatment,the levels of serum BDNF in both groups significantly increased(P〈0.01),while no significant difference was found between the two groups(P〈0.05).The N400 latency reduced and N400 amplitude increased in congruent condition in the two groups(P〈0.01),and under the incongruent conditions,the N400 latency was shortened(P〈0.05) in the paliperidone group and the N400 amplitude of the risperidone group was increased(P〈0.01).After the treatment,the total scores of PANSS in both groups decreased significantly(P〈0.01),but the difference between the groups was not significant(P〉0.05).A positive correlation between the rate of PANSS reduction and the increasing value of serum BDNF after the treatment was found in the paliperidone group(r = 0.417,P〈0.05),but it was not found in the risperidone group(r = 0.103,P = 0.516).CONCLUSION Both paliperidone and risperidone could increase the serum BDNF concentration in patients with schizophrenia and improve the cognitive function of patients(N400 latency and amplitude).
作者 孔令光 张伟 徐大利 谢海龙 陈兴时 林治光 张明岛 吴荣琴 KONG Ling-guang;ZHANG Wei;XU Da-li;XIE Hal-long;CHEN Xing-shi;LIN Zhi- guang;ZHANG Ming-dao;WU Rong-qin(Department of Clinical Laboratory, Wenzhou Seventh People's Hospital, Wenzhou ZHEJIANG 325000 China;Department of Electrophysiology, Shanghai Mental Health Center, Shanghai Jiaotong University, SHANGHAI 200030, China;Department of Psychiatry, Shanghai Jingan Mental Health Center, SHANGHAI 200436, China)
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2018年第5期304-308,共5页 Chinese Journal of New Drugs and Clinical Remedies
基金 国家自然科学基金(81471357) 温州市科技局项目基金(Y20160514)
关键词 帕利哌酮 利培酮 精神分裂症 脑源性神经营养因子 事件相关电位 认知 paliperidone risperidone schizophrenia brain-derived neurotrophic factor event-related potentials cognition
  • 相关文献

参考文献3

二级参考文献36

  • 1陈兴时,张明岛.惊跳反射弱刺激抑制的研究[J].神经病学与神经康复学杂志,2007(1):55-59. 被引量:5
  • 2翟金国,赵靖平,房茂胜.新型非典型抗精神病药临床应用评价[J].中国新药与临床杂志,2006,25(4):296-301. 被引量:42
  • 3BISHARA D, TAYLOR D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability[J]. Drugs, 2008, 68 (16): 2269-2292.
  • 4FOWLER JA, BETTINGER TL, ARGO TR. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia[J]. Clin Ther, 2008, 30(2) : 231-248.
  • 5LIEBERMAN JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs, 2004, 18(4) : 251-267.
  • 6CITROME L. Paliperidone: quo vadis?[J]. Int J Clin Pract, 2007, 61(4): 653-662.
  • 7ARAVAGIRI M, MARDER SR, NUECHTERLEIN KH, et al. Intra and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone[J]. Ther Drug Monit, 2003, 25 (6) : 657-664.
  • 8HERBERT Y, MELTER MD,WILLIAM V, et al. Efficacy and tolerability of oral pailiperidone extended-releaase tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies[J]. J Clin Psychiatry, 2008,69 (5): 817-829.
  • 9KRAMER M, SIMPSON G, MACIULIS V, et al. Pailiperidone extended-releaase tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study[J]. J Clin Psychopharmocol, 2007, 27 (1): 6-14.
  • 10CANUSO CM, YOUSSEF EA, BOSSIE CA, et al. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone[J]. Int Clin Psychopharmacol, 2008, 23 (4) : 209-215.

共引文献8

同被引文献121

引证文献12

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部